BioCryst Pharmaceuticals Inc logo

BCRX - BioCryst Pharmaceuticals Inc Share Price

$9.16 -0.1  -0.5%

Last Trade - 25/01/21

Mid Cap
Market Cap £1.19bn
Enterprise Value £1.14bn
Revenue £39.1m
Position in Universe 2292nd / 6623
Unlock BCRX Revenue
Relative Strength (%)
1m +17.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.83%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
13.6 48.3 26.4 25.2 20.7 48.8 32.1 53.9 +29.1%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,BioCryst Pharmaceuticals, Inc. revenues increased 51% to$13.8M. Net loss increased 15% to $122.3M. Revenues reflectCollaborative and other research and dev increase from$3.6M to $8.9M, Product sales increase of 34% to $2.7M.Higher net loss reflects General & Administrative increaseof 76% to $46.9M (expense), Research and developmentincrease of 9% to $87.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BCRX
Graphical History


BCRX Revenue Unlock BCRX Revenue

Net Income

BCRX Net Income Unlock BCRX Revenue

Normalised EPS

BCRX Normalised EPS Unlock BCRX Revenue

PE Ratio Range

BCRX PE Ratio Range Unlock BCRX Revenue

Dividend Yield Range

BCRX Dividend Yield Range Unlock BCRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BCRX EPS Forecasts Unlock BCRX Revenue
Profile Summary

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated November 15, 1991
Public Since March 4, 1994
No. of Shareholders: 145
No. of Employees: 140
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 176,565,622
Free Float (0.0%)
Eligible for
BCRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BCRX
Upcoming Events for BCRX
Wednesday 3rd March, 2021 Estimate
Q4 2020 BioCryst Pharmaceuticals Inc Earnings Release
Tuesday 4th May, 2021 Estimate
Q1 2021 BioCryst Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for BioCryst Pharmaceuticals Inc
What is the BioCryst Pharmaceuticals Inc share price?

As of 25/01/21, shares in BioCryst Pharmaceuticals Inc are trading at $9.16, giving the company a market capitalisation of £1.19bn. This share price information is delayed by 15 minutes.

How has the BioCryst Pharmaceuticals Inc share price performed this year?

Shares in BioCryst Pharmaceuticals Inc are currently trading at $9.16 and the price has moved by 0.207k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioCryst Pharmaceuticals Inc price has moved by 0.163k% over the past year.

What are the analyst and broker recommendations for BioCryst Pharmaceuticals Inc?

Of the analysts with advisory recommendations for BioCryst Pharmaceuticals Inc, there are there are currently 2 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioCryst Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will BioCryst Pharmaceuticals Inc next release its financial results?

BioCryst Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the BioCryst Pharmaceuticals Inc dividend yield?

BioCryst Pharmaceuticals Inc does not currently pay a dividend.

Does BioCryst Pharmaceuticals Inc pay a dividend?

BioCryst Pharmaceuticals Inc does not currently pay a dividend.

When does BioCryst Pharmaceuticals Inc next pay dividends?

BioCryst Pharmaceuticals Inc does not currently pay a dividend.

How do I buy BioCryst Pharmaceuticals Inc shares?

To buy shares in BioCryst Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioCryst Pharmaceuticals Inc?

Shares in BioCryst Pharmaceuticals Inc are currently trading at $9.16, giving the company a market capitalisation of £1.19bn.

Where are BioCryst Pharmaceuticals Inc shares listed? Where are BioCryst Pharmaceuticals Inc shares listed?

Here are the trading details for BioCryst Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BCRX
What kind of share is BioCryst Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, BioCryst Pharmaceuticals Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioCryst Pharmaceuticals Inc share price forecast 2021?

Shares in BioCryst Pharmaceuticals Inc are currently priced at $9.16. At that level they are trading at 24.21% discount to the analyst consensus target price of 0.00.

Analysts covering BioCryst Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.976 for the next financial year.

How can I tell whether the BioCryst Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioCryst Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 74%. At the current price of $9.16, shares in BioCryst Pharmaceuticals Inc are trading at 91.6% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioCryst Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for BioCryst Pharmaceuticals Inc.

Who are the key directors of BioCryst Pharmaceuticals Inc?

BioCryst Pharmaceuticals Inc's management team is headed by:

Jon Stonehouse - CEO
William Sheridan - SVP
Yarlagadda Babu - SVP
Kenneth Lee - IND
George Abercrombie - IND
Nancy Hutson - IND
Alane Barnes - SVP
Robert Ingram - CHM
Theresa Heggie - IND
Stephen Aselage - IND
Megan Sniecinski - SVP
Michael Jones - CAO
Charles Gayer - SVP
Allen Hodge - VPR
Anthony Doyle - CFO
Who are the major shareholders of BioCryst Pharmaceuticals Inc?

Here are the top five shareholders of BioCryst Pharmaceuticals Inc based on the size of their shareholding:

State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 10.17% (18.0m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.77% (13.7m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 7.19% (12.7m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 6.5% (11.5m shares)
Citadel Advisors LLC Hedge Fund
Percentage owned: 4.91% (8.66m shares)
Similar to BCRX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.